Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ocugen

0.7170
+0.02954.29%
Post-market: 0.7100-0.0070-0.98%19:22 EDT
Volume:3.19M
Turnover:2.30M
Market Cap:209.37M
PE:-3.59
High:0.7499
Open:0.7100
Low:0.6988
Close:0.6875
Loading ...

Ocugen Says Potential Retinitis Pigmentosa Therapy Improves Visual Acuity in Phase 1/2 Trial

MT Newswires Live
·
13 Jan

Ocugen reports ‘positive’ update from Phase 1/2 OCU400 trial

TIPRANKS
·
13 Jan

BRIEF-Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations From Phase 1/2 Clinical Trial Of Ocu400

Reuters
·
13 Jan

Ocugen Inc - Phase 3 Ocu400 Trial on Target for Bla Submission in 2026

THOMSON REUTERS
·
13 Jan

Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations From Phase 1/2 Clinical Trial of Ocu400 —a Novel Modifier Gene Therapy for Retinitis Pigmentosa

THOMSON REUTERS
·
13 Jan

Ocugen Inc - Ocu400 Shows Favorable Long-Term Safety and Tolerability

THOMSON REUTERS
·
13 Jan

Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa

GlobeNewswire
·
13 Jan

Ocugen Inc. Stock Falls Friday, Underperforms Market

Dow Jones
·
11 Jan

Ocugen Inc. Stock Falls Wednesday, Underperforms Market

Dow Jones
·
09 Jan

Ocugen Inc. Stock Rises Monday, Outperforms Market

Dow Jones
·
07 Jan

BRIEF-Ocugen Inc - On Dec 31, 2024 Receives Nasdaq Notice For Bid Price Deficiency

Reuters
·
04 Jan

Ocugen Inc - on Dec 31, 2024 Receives Nasdaq Notice for Bid Price Deficiency

THOMSON REUTERS
·
04 Jan

Ocugen Inc. Stock Rises Thursday, Outperforms Market

Dow Jones
·
03 Jan

Ocugen Inc. Stock Falls Monday, Underperforms Market

Dow Jones
·
31 Dec 2024

Ocugen Inc. Stock Rises Thursday, Outperforms Market

Dow Jones
·
27 Dec 2024

Ocugen Inc. Stock Falls Monday, Underperforms Market

Dow Jones
·
24 Dec 2024

5 Biotech Breakthrough Stocks to Watch in 2025

Zacks
·
23 Dec 2024

Ocugen Inc. Stock Rises Thursday, Outperforms Market

Dow Jones
·
20 Dec 2024

Ocugen Secures Data and Safety Monitoring Board Approval to Advance OCU410 Trial for Geographic Atrophy

MT Newswires Live
·
19 Dec 2024

Ocugen Inc - Dsmb Approves Continuation of Ocu410 Armada Phase 1/2 Study

THOMSON REUTERS
·
19 Dec 2024